Evidence map›Paper›PMID 36917274›Full record

ArticleApplied microbiology and biotechnology2023

Improving the on-target activity of high-fidelity Cas9 editors by combining rational design and random mutagenesis.

Daria S Spasskaya, Artem I Davletshin, Stanislav S Bachurin, Vera V Tutyaeva, David G Garbuz, Dmitry S Karpov

Abstract read
PubMed Publisher
In one paragraph

Article in Applied microbiology and biotechnology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Engineering Cas9: next generation of genomic editors.Applied microbiology and biotechnology · 2024
    Review
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Daria S SpasskayaCenter for Precision Genome Editing and Genetic Technologies for Biomedicine, Engelhardt Institute of Molecular Biology Russian Academy of Sciences, Vavilov St. 32, Moscow, 119991, Russia.
Artem I DavletshinEngelhardt Institute of Molecular Biology Russian Academy of Sciences, Vavilov St. 32, Moscow, 119991, Russia.
Stanislav S BachurinFSBEI HE Rostov State Medical University Ministry of Health, Nakhichevanskiy Lane 29, Rostov-On-Don, 344022, Russia.
Vera V TutyaevaCenter for Precision Genome Editing and Genetic Technologies for Biomedicine, Engelhardt Institute of Molecular Biology Russian Academy of Sciences, Vavilov St. 32, Moscow, 119991, Russia.
David G GarbuzCenter for Precision Genome Editing and Genetic Technologies for Biomedicine, Engelhardt Institute of Molecular Biology Russian Academy of Sciences, Vavilov St. 32, Moscow, 119991, Russia.
Dmitry S KarpovCenter for Precision Genome Editing and Genetic Technologies for Biomedicine, Engelhardt Institute of Molecular Biology Russian Academy of Sciences, Vavilov St. 32, Moscow, 119991, Russia. aleom@yandex.ru.ORCID http://orcid.org/0000-0001-5203-0787

Funding

Ministry of Science and Higher Education of the Russian Federation 075-15-2019-1660Russian Science Foundation 22-14-00377
6 · The paper itself

Abstract

Genomic and post-genomic editors based on CRISPR/Cas systems are widely used in basic research and applied sciences, including human gene therapy. Most genome editing tools are based on the CRISPR/Cas9 type IIA system from Streptococcus pyogenes. Unfortunately, a number of drawbacks have hindered its application in therapeutic approaches, the most serious of which is the relatively high level of off-targets. To overcome this obstacle, various high-fidelity Cas9 variants have been created. However, they show reduced on-target activity compared to wild-type Cas9 possibly due to increased sensitivity to eukaryotic chromatin. Here, we combined a rational approach with random mutagenesis to create a set of new Cas9 variants showing high specificity and increased activity in Saccharomyces cerevisiae yeast. Moreover, a novel mutation in the PAM (protospacer adjacent motif)-interacting Cas9 domain was found, which increases the on-target activity of high-fidelity Cas9 variants while retaining their high specificity. The obtained data suggest that this mutation acts by weakening the eukaryotic chromatin barrier for Cas9 and rearranging the RuvC active center. Improved Cas9 variants should further advance genome and post-genome editing technologies. KEY POINTS: • D147Y and P411T mutations increase the activity of high-fidelity Cas9 variants. • The new L1206P mutation further increases the activity of high-fidelity Cas9 variants. • The L1206P mutation weakens the chromatin barrier for Cas9 editors.

Indexed as

CRISPR-Cas SystemsChromatinGene EditingHumansMutagenesisRNA, Guide, CRISPR-Cas SystemsChromatinRNA, Guide, CRISPR-Cas SystemsCRISPR/Cas9Genome editingHigh-fidelity Cas9 variantsOn-target activity

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.